Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.70 |
| ▸ | HRH1 | P35367 | 2/20 | 0.51 |
| ▸ | IKBKB | O14920 | 1/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.47 |
| ▸ | PRKACA | P17612 | 1/20 | 0.47 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.47 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.47 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.47 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.47 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.47 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.47 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.47 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.47 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8055535 | 0.92 | HRH3 (0.68) | HRH3HRH1IKBKBROCK1ROCK2 | |
| SCHEMBL15088504 | 0.84 | HRH3 (0.71) | HRH3HRH1IKBKBHTR2CCYP2D6 | |
| SCHEMBL3085867 | 0.83 | HRH3 (1.00) | HRH3CYP2D6 | |
| SCHEMBL3077588 | 0.83 | HRH3 (0.95) | HRH3CYP2D6 | |
| SCHEMBL2299454 | 0.83 | SLC6A4 (0.54) | HRH3ROCK1HTR2CCYP2D6 | |
| SCHEMBL21461282 | 0.82 | HRH3 (0.51) | HRH3HRH1ROCK1ROCK2PRKACA | |
| SCHEMBL20324756 | 0.82 | HRH3 (0.51) | HRH3HRH1IKBKBROCK1ROCK2 | |
| SCHEMBL19023114 | 0.82 | HRH3 (0.53) | HRH3HRH1IKBKBROCK1ROCK2 | |
| SCHEMBL21461293 | 0.81 | HRH3 (0.53) | HRH3HRH1IKBKBROCK1ROCK2 | |
| SCHEMBL29594399 | 0.81 | HRH3 (0.53) | HRH3HRH1IKBKBROCK1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7307090-B2 | Piperidine derivatives useful as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2007-12-11 | — | — | US | disclosed |
| US-7265227-B2 | Piperidine derivatives useful as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2007-09-04 | — | — | US | disclosed |
| US-20070179297-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2007-08-02 | — | — | US | disclosed |
| US-7238811-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-07-03 | — | — | US | disclosed |
| US-7179922-B2 | 4-Phenyloxypiperidionopiperidine compounds as antiinflammatory agents; autoimmune diseases; rheumatic diseases; cardiovascular disorders | ASTRAZENECA AB (SE) | 2007-02-20 | — | — | US | disclosed |
| EP-1404667-B1 | PIPERIDINE DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2006-03-08 | — | — | EP | disclosed |
| EP-1604982-A1 | INTERMEDIATES FOR THE PREPARATION OF PIPERIDINE DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2005-12-14 | — | — | EP | disclosed |
| US-20050171092-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2005-08-04 | — | — | US | disclosed |
| US-6903115-B2 | Bipiperidine compounds | ASTRAZENECA AB (SE) | 2005-06-07 | — | — | US | disclosed |
| EP-1493743-A1 | Substituted bipiperidine intermediates and derivatives thereof | AstraZeneca AB (SE) | 2005-01-05 | — | — | EP | disclosed |
| US-6525070-B2 | For therapy of chemokine (such as CCR3) or H1 mediated disease state | ASTRAZENECA AB (SE) | 2003-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171092-A1 | Chemical compounds | CCR3, CCR1, CCR4 | HRH3 29/4885HRH1 38/4885IKBKB 782/4885 |
| US-20070179297-A1 | Chemical compounds | CCR3, CCR1, CCR4 | HRH3 29/4885HRH1 38/4885IKBKB 782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.